A phase II trial of mitomycin in patients with epithelial ovarian carcinoma resistant to cisplatin or carboplatin.
Intravenous bolus mitomycin was given at a dose of 10-12 mg/m2 to patients with epithelial ovarian cancer resistant to cisplatin or carboplatin. There were three (12%) partial responses and no complete responses in the 25 patients so treated.
Hoskins
P J
PJ
A. Maxwell Evans Clinic, Cancer Control Agency of British Columbia, Vancouver, Canada.
McMurtrie
E
E
Swenerton
K D
KD
D000328:Adult; D000368:Aged; D016190:Carboplatin / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D002945:Cisplatin / Q000627:therapeutic use*; D004341:Drug Evaluation; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D008937:Mitomycins / Q000009:adverse effects / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012074:Remission Induction; D013921:Thrombocytopenia / Q000139:chemically induced
D008937:Mitomycins; D016190:Carboplatin; D002945:Cisplatin